| Trial ID: | L3608 |
| Source ID: | NCT04321395
|
| Associated Drug: |
Vigabatrin
|
| Title: |
Vigabatrin and Insulin Sensitivity
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
YES
|
| Results: |
https://ClinicalTrials.gov/show/NCT04321395/results
|
| Conditions: |
NAFLD|Obesity
|
| Interventions: |
DRUG: Vigabatrin
|
| Outcome Measures: |
Primary: Insulin Sensitivity, Measured by hyperglycemic euglycemic clamp, 3 weeks after initiation of treatment | Secondary: Oral Glucose Tolerance, Measured by 75 gram oral glucose tolerance test, 3 weeks after initiation of treatment|Oral Glucose Insulin Sensitivity, Insulin sensitivity based on oral glucose tolerance. Values are calculated using glucose and insulin from a 3-hour 75 gram oral glucose tolerance test at 0, 2, and 3 hours. Higher values are indicate better insulin sensitivity., After 3 weeks on drug
|
| Sponsor/Collaborators: |
Sponsor: Washington University School of Medicine
|
| Gender: |
ALL
|
| Age: |
ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
4
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: OTHER
|
| Start Date: |
2021-08-23
|
| Completion Date: |
2024-05-15
|
| Results First Posted: |
2025-01-14
|
| Last Update Posted: |
2025-01-14
|
| Locations: |
Washington University in St. Louis, Saint Louis, Missouri, 63110, United States
|
| URL: |
https://clinicaltrials.gov/show/NCT04321395
|
